US Congress Senate Bill 1239 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 5-0)
Status: Introduced on June 27 2013 - 25% progression, died in committee
Action: 2013-06-27 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]

Scleroderma Research and Awareness Act - Requires the Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand, intensify, and coordinate the Institute's activities with respect to scleroderma, with particular emphasis on: (1) research focused on the etiology of scleroderma and the development of new treatment options, (2) clinical research to evaluate new treatment options, (3) basic research on the relationship between scleroderma and secondary conditions, (4) establishment of scleroderma patient registries, and (5) support for training of new clinicians and investigators with expertise in scleroderma. Directs the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC), to carry out an educational campaign to increase public awareness of scleroderma.

Scleroderma Research and Awareness Act

Sen. Kirsten Gillibrand [D-NY]	Sen. Dianne Feinstein [D-CA]	Sen. Christopher Murphy [D-CT]	Sen. Charles Schumer [D-NY]
Sen. Debbie Stabenow [D-MI]

Date	Chamber	Action
2013-06-27	Senate	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

HB1429 (Related) 2013-04-12 - Referred to the Subcommittee on Health.

Type	Source
Summary	https://www.congress.gov/bill/113th-congress/senate-bill/1239/all-info
Text	https://www.congress.gov/113/bills/s1239/BILLS-113s1239is.pdf